WPS testing and clinical evidence

DNA strand for Precision Medicine

WPS testing and clinical evidence

WPS Gene/drug pair evidence database

Whole Pharmacogenomics Scan (WPSTM)  is the most comprehensive PGx testing platform available today. It analyzes nearly 1,200 genes and markers that impact drug responses and supported by clinical evidence curated and recognized by PharmGKB.

Clinical interpretation of the WPS is based on peer-reviewed clinical evidence curated by Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB.

Due to the scope of the test, only the gene/drug pairs with CPIC level are shown. If the genes and drugs you are interested in are not shown in the list, there is a good chance that they are still included in the WPS. Please contact or email us to determine whether the genes you are interested in are included in the WPS test.

We work closely with our customers to create a customized clinical report that aligns with their medical practice.

 

SEARCH BY GENE or DRUG NAME

Search the clinical evidence database for WPS gene/drug pairs with CPIC level.

Clinical Evidence

CPIC

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium facilitating the clinical implementation of pharmacogenetic tests for improved patient care.

CPIC’s goal is to translate genetic laboratory test results into actionable prescribing decisions for affected drugs by creating, curating, and posting the latest information for free. This peer-reviewed and evidence-based database would be updatable and contain detailed gene/drug clinical practice guidelines.

PharmGKB

The Pharmacogenomics knowledge base (PharmGKB) is a National Institute of Health (NIH)-funded resource that provides information about how human genetic variation affects response to medications. PharmGKB collects, curates, and disseminates knowledge about clinically actionable gene-drug associations and genotype-phenotype relationships.

Table of PGx biomarkers in drug labeling, approved by the FDA

The U.S. Food and Drug Administration (FDA) maintains a list of labels containing PGx information called the “Table of PGx Biomarkers in Drug Labels”. Drug labeling may contain information on genomic biomarkers and can describe drug-associated clinical response variability, risk for adverse events, genotype-specific dosing, and mechanisms of drug action., Moreover, clinical trial design features, polymorphic drug targets, and disposition genes may also be described.

Testing menu

At RPRD, we offer a range of PGx testing service including targeted PGx panels, comprehensive Whole Pharmacogenomics Scan (WPS), and tailored solutions using genotyping platforms or NGS.